About Anthology
Anthology is a Healthcare company based in Cambridge (United States) founded in 2023 by Jing Zhang, Tzu-Chieh Tang, and Charles Jo. Diverse genomes are generated to scale biomanufacturing and digitalize processes. It operates on a Product-as-a-Service model. Its chief executive, as recorded, is Jing Zhang. Anthology offers products and services including Designer Genomes, Functional Proteins, and Engineered Microbes. Its focus areas include Biotechnology, Synthetic Biology and Genomic Engineering. Its competitors include Tessera Therapeutics, Phase Genomics and Strateos; 3 of its 3 listed competitors have raised funding.
Company details
Anthology is focused on generating diverse designer genomes to address challenges in human, animal, and planetary health. Solutions are developed in the biotechnology sector, emphasizing synthetic biology and genomic engineering. Functional proteins are produced for healthy aging and animal welfare, while engineered microbes support carbon-neutral bioproduction by converting waste into valuable products. Scalable and efficient approaches are prioritized to promote a circular bioeconomy and reduce environmental impact.
- Headquarters Cambridge, United States
- Founders Jing Zhang, Tzu-Chieh Tang, Charles Jo
- SectorsHealthcare
- Website anthology.bio
- Social LinkedIn
- Investors
Products & Services of Anthology
Anthology offers a comprehensive portfolio of products and services, including Designer Genomes, Functional Proteins, and Engineered Microbes.
Designer genomes are created for diverse biomanufacturing applications.
Functional proteins are produced for healthy aging support.
Engineered microbes are used for carbon-neutral waste conversion.
Funding Insights of Anthology
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Anthology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | Seed | – | Climate Capital | – |
1 investors in total: 1 institutional.
Investors in Anthology
Anthology has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Climate Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is invested in climate tech startups and entrepreneurs. | climatecapital.co | San Francisco, United States |
Investor details for Anthology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Anthology
3 people are tracked at Anthology (3 in leadership).
| Name | Role | Group |
|---|---|---|
Jing Zhang | Co-Founder & CEO | Leadership |
Tzu-Chieh Tang | Co-Founder | Leadership |
Charles Jo | Co-Founder | Leadership |
Complete people profiles for Anthology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Anthology
2 dated milestones of Anthology, from founding to its latest funding, stage changes and deals.
- Founded Anthology is founded.
- Funding First funding round.
Competitors of Anthology
Anthology has 3 listed competitors in our database, 3 of them funded. They include Tessera Therapeutics, Phase Genomics and Strateos.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tesseratherapeutics.com | 2017 | Cambridge, United States | $610M | 149 | New genome engineering technology is provided for treating multiple diseases. | |
| phasegenomics.com | 2015 | Seattle, United States | $5.75M | 19 | Laboratory and computational services for DNA proximity analysis are provided. | |
| strateos.com | 2019 | Menlo Park, United States | $72.6M | 147 | Provider of cloud based platform provides data driven information for biotech research |
Detailed competitors of Anthology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Anthology (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Anthology
Anthology was founded in 2023.
Anthology is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Jing Zhang is the CEO of Anthology, as recorded in our data. They have also founded this company.
Anthology is focused on generating diverse designer genomes to address challenges in human, animal, and planetary health. Solutions are developed in the biotechnology sector, emphasizing synthetic biology and genomic engineering. Functional proteins are produced for healthy aging and animal welfare, while engineered microbes support carbon-neutral bioproduction by converting waste into valuable products. Scalable and efficient approaches are prioritized to promote a circular bioeconomy and reduce environmental impact.
Anthology's top competitors include Tessera Therapeutics, Phase Genomics and Strateos.
Anthology offers Designer Genomes, Functional Proteins, and Engineered Microbes.
Anthology has 1 investor. Key investors include Climate Capital.